CVS Health’s compact Houston pharmacy could reveal where America’s drugstores are heading
CVS Health opens a pharmacy-focused Houston store as its smaller format tests whether better access can coexist with stronger retail economics for patients.
Pharma & Biotech
Pharma & Biotech
Can one gene therapy cut years of eye injections? REGENXBIO’s five-year data raise the stakes
REGENXBIO reports five-year wet AMD durability and 2.5-year diabetic retinopathy data as pivotal sura-vec milestones approach.
Pharma & Biotech
Vanda’s imsidolimab has won a rare European advantage, but one approved rival changes the equation
Vanda’s imsidolimab gains an EMA orphan recommendation for GPP, but approval, differentiation and European access remain ahead.
Pharma & Biotech
CAM2029 is back before the FDA, but has Camurus finally cleared its manufacturing hurdle?
Camurus has restored a formal United States review timeline for CAM2029, but the December decision remains tied to third-party manufacturing compliance rather than new questions about clinical efficacy.
Pharma & Biotech
Could calpurbatug spare infected joint implants? Trellis Bioscience raises $9m to find out
Trellis Bioscience raises $9 million to complete a Phase 2 trial testing calpurbatug and implant retention in chronic joint infections.
Pharma & Biotech
Anova and Nouveau Biosciences partner on Phase 1 Kromastat trial in T-cell lymphoma
Anova will manage Kromastat’s first-in-human Phase 1 trial as Nouveau Biosciences tests a nanoparticle approach in T-cell lymphomas.
Pharma & Biotech
GemPharmatech just added a humanized liver model, but can it close the clinical translation gap?
GemPharmatech and Humlab Global expand access to humanized mouse models, but validation and adoption will determine their clinical value.
Pharma & Biotech
FDA gives Genentech’s Gazyva Priority Review for primary membranous nephropathy
FDA Priority Review puts Genentech’s Gazyva on a November decision path in primary membranous nephropathy after the Phase III MAJESTY win.
Pharma & Biotech
Can VDPHL01 carry its male-trial momentum into women? Veradermics is about to show the data
See why Veradermics’ Study 207 female data could shape VDPHL01 dose selection, safety expectations and its Phase 3 clinical strategy.
Pharma & Biotech
Why Kelun-Biotech’s latest sac-TMT Phase III result could matter more than the headline suggests
Kelun-Biotech reports improved Phase III PFS with sac-TMT plus pembrolizumab, while survival and detailed safety data remain pending.